Valuation : MediciNova, Inc.

Market Cap 79.74M 68.61M 64.56M 58.97M 110M 7.53B 111M 763M 296M 3.86B 299M 293M 12.44B P/E 2026 *
-6.15x
P/E 2027 * -4.26x
Enterprise Value 79.74M 68.61M 64.56M 58.97M 110M 7.53B 111M 763M 296M 3.86B 299M 293M 12.44B EV / Sales 2026 *
103x
EV / Sales 2027 * 159x
Free-Float
97.13%
Yield 2026 *
-
Yield 2027 * -
08-13 MediciNova, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-15 Medicinova Achieves Target Enrollment in Seanobi-Als Study Evaluating Mn-166 in Als Patients CI
06-08 MediciNova Receives Notice Of Allowance For New Patent Covering Use Of MN-166 In Combination With Anti-PD-1 Immune Checkpoint Inhibitor For Glioblastoma Treatment CI
06-08 MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer MT
05-27 MediciNova Announces Completion Of Last Patient Last Visit In The MN-001-NATG-202 Clinical Trial Of MN-001 CI
05-14 MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-16 HC Wainwright Initiates MediciNova at Buy With $10 Price Target MT
02-20 MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-30 MediciNova, Inc. Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access- Program Evaluating MN-166 in ALS Patients CI
12-30 MediciNova Inc enters $50 million equity distribution agreement with Lucid Capital Markets RE
12-18 MediciNova, Inc. Announces Completion of Patient Enrollment Evaluating MN-166 in the Prevention of Chemotherapy-Induced Peripheral Neuropathy CI
12-18 MediciNova Completes Enrollment in a Phase 2 Study of Colorectal Cancer Drug MT
12-08 MediciNova, Inc. Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 in ALS (COMBAT-ALS) in ALS Presented at the 36th International Symposium on ALS/MND CI
1 day-2.16%
1 week+10.80%
Current month+10.80%
1 month+22.31%
3 months+20.45%
6 months+10.42%
Current year+21.37%
1 week 1.42
Extreme 1.42
1.63
1 month 1.3
Extreme 1.3001
1.63
Current year 1.22
Extreme 1.22
1.92
1 year 1.17
Extreme 1.168
1.96
3 years 1.12
Extreme 1.12
2.55
5 years 1.12
Extreme 1.12
4.65
10 years 1.12
Extreme 1.12
14.5
Manager TitleAgeSince
Chief Executive Officer 76 01/08/2005
Director of Finance/CFO 49 16/06/2022
Chief Tech/Sci/R&D Officer 60 01/09/2011
Director TitleAgeSince
Chairman 76 26/09/2000
Director/Board Member 60 24/07/2019
Director/Board Member 69 01/09/2004
Date Insider Type Main position Quantity % Market Cap. Importance
1/16/26 A Free

Chief Technology Officer

350,000 0.7122%
1/16/26 A Free

Chief Executive Officer

450,000 0.9156%
6/17/25 A Free

Director

20,000 0.0408%
Change 5-day change 1-year change 3-year change Capi.($)
-2.16%+10.80%+18.29%-31.47% 79.74M
-1.79%-3.82%+38.74%+91.90% 69.02B
-2.06%-0.18%+41.53%+88.17% 66.32B
-0.43%+6.77%-11.20%+379.96% 27.66B
+1.39%+2.06%+0.66%-14.60% 25.84B
-3.00%-2.61%+34.45%+11.39% 26.54B
-1.46%+0.42%+24.07%-18.70% 20.4B
-2.96%-16.03%+213.13%+375.00% 17.63B
-1.49%-6.69%-4.69%+539.74% 15.15B
-0.34%+8.50%+58.05%+165.29% 14.65B
Average -1.41%+0.81%+41.30%+158.67% 28.33B
Weighted average by Cap. -1.49%-0.45%+39.11%+139.26%

Financials

2026 *2027 *
Net sales 772K 665K 625K 571K 1.07M 72.94M 1.07M 7.39M 2.87M 37.42M 2.9M 2.84M 121M 500K 430K 405K 370K 692K 47.21M 694K 4.78M 1.86M 24.22M 1.88M 1.84M 78.03M
Net income -13.39M -11.52M -10.84M -9.9M -18.53M -1.26B -18.58M -128M -49.71M -649M -50.28M -49.18M -2.09B -22.3M -19.19M -18.06M -16.5M -30.86M -2.11B -30.94M -213M -82.8M -1.08B -83.76M -81.93M -3.48B
Net Debt - -
Logo MediciNova, Inc.
MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.
Employees
6
Date Price Change Volume
04/09/26 $1.590 -1.85% 48,059
03/09/26 $1.620 +13.29% 111,260
02/09/26 $1.430 -0.69% 14,304
01/09/26 $1.440 +0.35% 19,970
31/08/26 $1.435 0.00% 18,670
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.620USD
Average target price
9.000USD
Spread / Average Target
+455.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNOV Stock